Seminars in Oncology
Volume 34, Issue 5 , Pages 379-383 , October 2007

Clinically Relevant Biology of Hereditary Breast Cancer

  • William D. Foulkes

      Affiliations

    • Corresponding Author InformationAddress correspondence to William D. Foulkes, MB, PhD, MRCP(UK), Associate Professor, Departments of Medicine, Oncology and Human Genetics, McGill University, 546 Pine Ave W, Montreal, Quebec H2W 156, Canada.

References 

  1. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998;90:1138–1145
  2. Honrado E, Osorio A, Palacios J, et al. Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. Oncogene. 2006;25:5837–5845
  3. Agnarsson BA, Jonasson JG, Bjornsdottir IB, et al. Inherited BRCA2 mutation associated with high grade breast cancer. Breast Cancer Res Treat. 1998;47:121–127
  4. Breast Cancer Linkage Consortium: Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet. 1997;349:1505–1510
  5. Bane AL, Beck JC, Bleiweiss I, et al. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol. 2007;31:121–128
  6. Jass JR. Role of the pathologist in the diagnosis of hereditary non-polyposis colorectal cancer. Dis Markers. 2004;20:215–224
  7. Armes JE, Egan AJ, Southey MC, et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: A population-based study. Cancer. 1998;83:2335–2345
  8. Thiffault I, Hamel N, Pal T, et al. Germline truncating mutations in both MSH2 and BRCA2 in a single kindred. Br J Cancer. 2004;90:483–491
  9. Johannsson OT, Idvall I, Anderson C, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer. 1997;33(3):362–371
  10. Karp SE, Tonin PN, Begin LR, et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer. 1997;80:435–441
  11. Foulkes WD, Metcalfe K, Sun P, et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res. 2004;10:2029–2034
  12. Lakhani SR, van de Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20:2310–2318
  13. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001;344:539–548
  14. Van’t Veer LJ, Dai HY, van de Vijver MJ. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536
  15. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418–8423
  16. Scully R, Chen J, Plug A, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell. 1997;88:265–275
  17. Sharan SK, Morimatsu M, Albrecht U, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature. 1997;386:804–810
  18. Mizuta R, Lasalle JM, Cheng HL, et al. RAB22 and RAB163/mouse BRCA2 - proteins that specifically interact with the RAD51 protein. Proc Natl Acad Sci U S A. 1997;94:6927–6932
  19. Wong AK, Pero R, Ormonde PA, et al. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem. 1997;272:31941–31944
  20. Moynahan ME, Cui TY, Jasin M. Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res. 2001;61:4842–4850
  21. Tassone P, Tagliaferri P, Perricelli A, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer. 2003;88:1285–1291
  22. Yuan SSF, Lee SY, Chen G, et al. BRCA2 is required for ionizing radiation-induced assembly of rad51 complex in vivo. Cancer Res. 1999;59:3547–3551
  23. Patel KJ, Yu VP, Lee H, et al. Involvement of Brca2 in DNA repair. Mol Cell. 1998;1:347–357
  24. Zhong Q, Chen CF, Li S, et al. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science. 1999;285:747–750
  25. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108:171–182
  26. Hartman AR, Ford JM. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat Genet. 2002;32:180–184
  27. Greenblatt MS, Chappuis PO, Bond JP, et al. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: Distinctive spectrum and structural distribution. Cancer Res. 2001;61:4092–4097
  28. Kojic M, Yang H, Kostrub CF, et al. The BRCA2-interacting protein DSS1 is vital for DNA repair, recombination, and genome stability in Ustilago maydis. Mol Cell. 2003;12:1043–1049
  29. Gudmundsdottir K, Lord CJ, Witt E, et al. DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells. EMBO Rep. 2004;5:989–993
  30. Xia B, Sheng Q, Nakanishi K, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell. 2006;22:719–729
  31. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002;297:606–609
  32. Offit K, Levran O, Mullaney B, et al. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst. 2003;95:1548–1551
  33. Reid S, Schindler D, Hanenberg H, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet. 2007;39:162–164
  34. Xia B, Dorsman JC, Ameziane N, et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet. 2007;39:159–161
  35. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007;39:165–167
  36. Tischkowitz M, Xia B, Sabbaghian N, et al. Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A. 2007;104:6788–6793
  37. Erkko H, Xia B, Nikkila J, et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007;446:316–319
  38. Mullan PB, Quinn JE, Harkin DP. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene. 2006;25:5854–5863
  39. Monteiro AN, August A, Hanafusa H. Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci U S A. 1996;93:13595–13599
  40. Abkevich V, Zharkikh A, Deffenbaugh AM, et al. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet. 2004;41:492–507
  41. Phelan CM, Dapic V, Tice B, et al. Classification of BRCA1 missense variants of unknown clinical significance. J Med Genet. 2005;42:138–146
  42. Hashizume R, Fukuda M, Maeda I, et al. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem. 2001;276:14537–14540
  43. Scully R, Anderson SF, Chao DM, et al. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci U S A May. 1997;94:5605–5610
  44. Rummukainen JK, Salminen T, Lundin J, et al. Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array. Mod Pathol. 2001;14:1030–1035
  45. Grushko TA, Dignam JJ, Das S, et al. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res. 2004;10:499–507
  46. Tirkkonen M, Johannsson O, Agnarsson BA, et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res. 1997;57:1222–1227
  47. Mai S, Garini Y. Oncogenic remodeling of the three-dimensional organization of the interphase nucleus: c-Myc induces telomeric aggregates whose formation precedes chromosomal rearrangements. Cell Cycle. 2005;4:1327–1331
  48. Wang Q, Zhang H, Kajino K, et al. BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. Oncogene. 1998;17:1939–1948
  49. Foulkes WD. BRCA1 functions as a breast stem cell regulator. J Med Genet. 2004;41:1–5
  50. Daniels MJ, Wang Y, Lee M, et al. Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science. 2004;306:876–879
  51. Delaval B, Ferrand A, Conte N, et al. Aurora B -TACC1 protein complex in cytokinesis. Oncogene. 2004;23:4516–4522

PII: S0093-7754(07)00148-0

doi: 10.1053/j.seminoncol.2007.07.010

Seminars in Oncology
Volume 34, Issue 5 , Pages 379-383 , October 2007

Article Tools